Ginkgo Biloba In CogniHoney: What The Safety Data Says

Ask “is ginkgo safe” and the honest answer is that it depends on what else is being taken. Two PubMed-indexed reviews looked at the bleeding question from different directions and reached different emphases, not a flat contradiction.

A 2011 meta-analysis pooled 18 randomized controlled trials, 1,985 adults in total, and measured standard laboratory markers of clotting — platelet aggregation, fibrinogen, clotting times. It found no statistically significant effect of standardized ginkgo extract on any of them.^{[Kellermann 2011]} A 2005 review took the opposite approach: it searched the published literature for case reports of an actual bleeding event in someone using ginkgo, and found 15, including 8 episodes of intracranial bleeding. Most of the people in those reports also had other risk factors for bleeding, which is why the review calls the association “possible” rather than proven.^{[Bent 2005]}

Read together, the two reviews say something more useful than either alone: routine lab markers of clotting look largely unaffected by standardized ginkgo extract in controlled trials, but real-world case reports of bleeding in ginkgo users exist and cannot be waved away, particularly for people who already carry a bleeding risk from another source. That is the shape of the safety data this article works through.

CogniHoney’s supplement facts panel names eleven ingredients in a two-capsule daily serving. Ginkgo biloba powder is the eighth name on that list, printed without a percentage, alongside six other names that also carry no percentage: Himalayan pink salt, cinnamon extract, AGP choline, bilberry leaf powder, vitamin B6 and vitamin B12. Only four of the eleven — bacopa monnieri, lutein, zeaxanthin and green tea extract — carry a printed percentage, and a separate note on this blog explains what that percentage does and does not disclose.

“Powder” on this line means the ingredient is a dried, ground leaf preparation rather than a solvent-extracted, standardized extract. That distinction matters for safety reading because most of the clinical research on ginkgo, including both reviews cited above, was conducted on standardized leaf extracts with a defined content of flavone glycosides and terpene lactones, not on unstandardized leaf powder. A powder is not guaranteed to carry the same concentration of those compounds as the extract used in a trial, in either direction. The supplement facts page sets out the full eleven-ingredient list line by line; this note only goes deep on one line of it.

The 2005 review, led by Stephen Bent at the University of California, San Francisco, searched MEDLINE, EMBASE, IBIDS and the Cochrane Collaboration Database from 1966 through October 2004 for published case reports describing a bleeding event in someone using ginkgo. Two reviewers independently assessed each report using a standard causality framework.^{[Bent 2005]}

Fifteen case reports met the criteria. Most described serious events, including eight episodes of intracranial bleeding. Thirteen of the fifteen reports identified another risk factor for bleeding in the same person — a blood thinner, an antiplatelet drug, a clotting disorder, or another herb with a similar effect — which is why the review is careful to call the link “possible” rather than proven for ginkgo alone. Only six reports clearly documented that ginkgo was stopped and the bleeding did not recur, and in the three reports that measured bleeding time directly, it was elevated while the person was taking ginkgo.

The review’s own conclusion is measured: a structured look at the published case reports “suggests a possible causal association” between ginkgo and bleeding, and given how widely the herb is used and how serious some of the reported events were, it recommends that ginkgo users with a known bleeding risk be counseled about it.^{[Bent 2005]} A case-report review cannot establish how often this happens across everyone who takes ginkgo — it only collects incidents that were unusual enough, and serious enough, to be written up and published. That is a real limitation, and it is also exactly why the events it does collect are worth taking seriously rather than dismissing as noise.

Working from the opposite direction, a 2011 meta-analysis by Kellermann and Kloft pooled 18 randomized, placebo-controlled trials of standardized Ginkgo biloba extract, covering 1,985 adults; 87% of participants had dementia, peripheral artery disease or diabetes, and 13% were healthy volunteers.^{[Kellermann 2011]} Rather than searching for reported bleeding events, this review measured what standardized ginkgo extract did to the laboratory numbers that predict bleeding risk: platelet aggregation, fibrinogen concentration, activated partial thromboplastin time (aPTT) and prothrombin time (PT).

Across the pooled trials, ginkgo showed a statistically significant improvement in blood viscosity, but no significant effect on ADP-induced platelet aggregation, fibrinogen concentration, aPTT or PT. In plain terms: on the specific lab tests doctors use to flag a bleeding risk before surgery or when adjusting a blood thinner, standardized ginkgo extract did not move the numbers in these pooled trials.

These two findings are not a contradiction once the study designs are laid side by side. A meta-analysis of controlled trials is good at detecting a moderate, consistent effect across a defined population under controlled dosing — and standardized ginkgo extract, on average, across mostly older adults with dementia, peripheral artery disease or diabetes, did not shift the routine clotting markers those trials measured. A case-report review is good at surfacing rare, serious events that a modestly sized trial would likely miss entirely, especially in people who were also taking another drug that affects clotting, or who had an undiagnosed bleeding tendency the trial’s inclusion criteria would have screened out.

Put differently: the trials say the average effect on standard lab tests is small. The case reports say that in specific people, particularly people already at elevated bleeding risk for another reason, a bleeding event that coincided with ginkgo use did happen and was serious enough to be published. Both things can be true, and the practical reading is the same one the FDA and NCCIH both give for supplement ingredients generally: an average finding across a study population does not rule out a real risk for a specific individual with a specific combination of medicines and conditions.

A 2017 systematic review of 22 studies on older adults who combined prescription medicines with herbal products found that ginkgo, garlic and ginseng together with aspirin or warfarin were the most frequently reported herb-drug interaction concern in the literature it reviewed — specifically the potential for added bleeding risk.^{[Agbabiaka 2017]} That review also found antihypertensives, anticoagulants, antiplatelet drugs, antidiabetics and antidepressants among the prescription categories most often combined with herbal products by older adults, without those combinations always being disclosed to a prescriber.

The National Center for Complementary and Integrative Health, part of the National Institutes of Health, keeps a public fact sheet on ginkgo that summarizes the same two-sided picture: ginkgo may increase the risk of bleeding, particularly in combination with blood-thinning medicines, and people should tell their health care providers about any ginkgo use before a surgical or dental procedure.^[NCCIH] It is a useful independent check against the two PubMed reviews above, written for a general audience rather than a clinical one, and it is not selling anything.

The ginkgo literature is a reasonable template for how to read safety claims about any herbal ingredient. Look for at least two kinds of study: a controlled trial or meta-analysis measuring an objective marker, and a case-report or pharmacovigilance review collecting real-world incidents. Ask what population each one studied — the meta-analysis above was mostly older adults with an existing health condition, not healthy younger adults. And treat a public fact sheet from a body like NCCIH as a useful cross-check, not a replacement for either kind of primary research, since it is written to summarize the literature rather than to generate new findings.

None of this is a verdict on whether ginkgo biloba powder is right for any one person to take. It is a summary of what has actually been published, so that the question “is this safe for me” can be asked of a pharmacist or prescriber with the right specifics in hand, rather than asked in the abstract.